Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study.
We conducted a tandem autologous stem cell transplantation procedure for patients with relapsed or refractory high-grade non-Hodgkin's lymphoma (HGNHL) or with transformation of indolent lymphoma (n=15). These patients had poor prognosis factors. The procedure was well tolerated, ten patients were in complete remission. Overall survival rate is 67%.